ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

CTNM vs CAPR // EV/EBITDA & P/E VALUATION

Contineum Therapeutics Inc. (Class A) (NASDAQ) VS. Capricor Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CTNM 3 — CAPR 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTNM VS. CAPR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC CTNM CAPR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -29.00% -35.00% +6.00 CTNM /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield -15.82% -18.86% +3.04 CTNM /fcf-yield <GO>
Operating Margin — — — TIE /operating-margins <GO>
Net Profit Margin — — — TIE /net-margins <GO>
Revenue Growth (YoY) — — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 3.38 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 43.2 42.3 +0.90 CTNM /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $353.3M $370.9M -$17.7M CAPR /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR CTNM REV CAPR REV CTNM GROSS % CAPR GROSS % CTNM FCF CAPR FCF
FY 2025 $190.6M $302.8M — — -$55.5M -$72.7M
FY 2024 $142.5M $22.3M — — -$33.4M -$41.2M
FY 2023 $50.0M $25.2M — — $19.3M -$25.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTNM // BETA —
CAPR // BETA —